采用GastroPlus 软件发表的部分参考文献汇总（2021年）

凡默谷技术部挑选了2021年全球应用GastroPlus 软件发表或涉及GastroPlus的部分应用文章。希望对您的业务或专业学习有所帮助。

采用PBPK/PD建模评估咪达唑仑直肠给药凝胶的吸收

Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling to Evaluate the Absorption of Midazolam Rectal Gel

Zhu J, Zhao Y, Wang L, Zhou C, Zhou S, Chen T, Zhang Z, Zhu Y, Ding S, Shao F. European Journal of Pharmaceutical Sciences. Volume 167, 1 December 2021, 106006. IF=5.112

PBPK模型是儿科药物开发的有效支持工具

Physiologically Based Pharmacokinetic Models Are Effective Support for Pediatric Drug Development

Wang K, Jiang K, Wei X, Li Y, Wang T, Song Y. AAPS PharmSciTech. 2021 Aug; 22(6): 208. IF=3.951

根据中国男性成年人的PK数据和PBPK建模，优化氨氯地平在儿童中的个体化给药策略

Optimization of Personalized Amlodipine Dosing Strategies for Children Based on Pharmacokinetic Data from Chinese Male Adults and PBPK Modeling

Han X, Hong X, Li X, Wang Y, Zheng A. Children. 2021, 8(11), 950.  IF=2.835

使用计算机和体外方法预测决明子中 26 种成分的潜在毒性

Predicting the potential toxicity of 26 components in Cassiae semen using in silico and in vitro approaches

Yang J, Wang S, Zhang T, Sun Y, Han L, Banahene PO, Wang Q. Current Research in Toxicology.  Volume 2, 2021, Pages 237-245. CiteScore =3.1

使用计算机模拟开发托匹司他速释片具有体内预测力的溶出方法

Development of an In Vivo Predictive Dissolution Methodology of Topiroxostat Immediate-Release Tablet Using In Silico Simulation

Li G, Yang H, Liu W, Shen C, Ji Y, Sun Y, Huo Q, Liu Y, Wang G. AAPS PharmSciTech. volume 22, Article number: 132 (2021). IF=3.951

通过PBPK模型调整头孢他啶在肾损伤儿科患者的给药剂量

Dosage Adjustment for Ceftazidime in Pediatric Patients With Renal Impairment Using Physiologically Based Pharmacokinetic Modeling

Zhou J, You X, Ke M, Ye L, Wu W, Huang P, Lin C. Journal of Pharmaceutical Sciences. Volume 110, Issue 4, April 2021, Pages 1853-1862. IF=3.784

采用PBPK建模预测特拉万星在肾功能不全的肥胖患者中的药代动力学

Application of physiologically based pharmacokinetic modeling to predict the pharmacokinetics of telavancin in obesity with renal impairment

Wu W, Ke M, Ye L, Lin C. European Journal of Clinical Pharmacology. volume 77, pages989–998 (2021) Published: 15 January 2021.  IF=3.064

使用PBPK模型优化头孢洛林在肾损伤儿科患者的给药剂量

Ceftaroline Dosage Optimized for Pediatric Patients With Renal Impairment Using Physiologically Based Pharmacokinetic Modeling

Jie Zhou, Xiang You, Guimu Guo, Meng Ke, Jianwen Xu, Lingling Ye, Wanhong Wu, Pinfang Huang, Cuihong Lin. The Journal of Clinical Pharmacology. Volume61, Issue12, December 2021, Pages 1646-1656.  IF=2.86

生理药动学模型在固体口服制剂一致性评价中的应用

胡昌勤. 《中国抗生素杂志》. 2021,46(03). 综合影响因子=1.255 

国产盐酸文拉法辛缓释胶囊的虚拟生物等效性

王茜，姜红，周茜，刘晨曦，赵亚萍. 《医药导报》2021年10月第40卷第10期.

综合影响因子= 1.253

国产盐酸地芬尼多片与原研制剂的溶出曲线和有关物质比较研究

朱荣，黄丽丽，朱健萍. 《药物分析杂志》2021,41(3). 综合影响因子= 1.418 

基于国家评价性抽检的盐酸丙卡特罗片质量分析与研究

程智，刘峰，谢华，张涌灵，罗岚，郭志渊.  《中国药事》 2021年7月 第35卷 第7期. 综合影响因子= 0.841

基于生理药代动力学模型从体外及临床前数据对人体药代动力学预测及优化应用状况

杨妍妍，谢潘潘，史爱欣. 《中国临床药理学杂志》 第37卷第20期 2021年10月.  综合影响因子= 1.225

基于体外溶出的格列美脲片人体生物等效性预测研究

刘文霞，何坚，张钰，田媛，张尊建. 《中国临床药理学杂志》 第37卷第10期 2021年5月. 综合影响因子= 1.225

盐酸克林霉素棕榈酸酯口服制剂的有效性评价

王晨，许明哲.《中国药物警戒》. 2021,18(07). 综合影响因子= 1.152

计算机模拟技术与平行人工膜渗透模型在富马酸比索洛尔片生物等效性豁免研究中的应用

郭志渊，谢华，雍子宜，唐敏，袁军. 《中国新药杂志》 2021年第30卷第6期.

综合影响因子= 1.148

GastroPlus 软件在预测甲苯磺酸索拉非尼片生物等效性中的应用

孙运栋，王小雷，曾金，曹祥，徐翰林. 《中国医药工业杂志》. 2021, 52(11).

综合影响因子= 0.648

质量源于设计(QbD)在干粉吸入剂开发中的应用

董子豪，吴闻哲. 《中国医药工业杂志》 2021, 52(2). 综合影响因子= 0.648

万古霉素联合多黏菌素B 用药对肾小管上皮细胞的作用

吉西他滨的渗透性，并用其PBPK模型评估口服给药后的情况

Permeability of Gemcitabine and PBPK Modeling to Assess Oral Administration

Ferreira A, Lapa R, Vale N. Curr. Issues Mol. Biol. 2021, 43(3), 2189-2198. IF=2.976

盐酸普萘洛尔的3D打印颊黏膜延释制剂：开发、表征、生物利用度预测

3D Printed Buccal Films for Prolonged-Release of Propranolol Hydrochloride: Development, Characterization and Bioavailability Prediction

Jovanović M, Petrovic M, Cvijić S, Tomić N, Stojanović D, Ibric S, Uskoković P. Pharmaceutics. 2021, 13(12), 2143. IF=6.51

CYP 450诱导的PBPK建模的当前实践，分析方法的鸿沟，建议的工作流程：工业界观点

Current Practices, Gap Analysis and Proposed Workflows for PBPK Modeling of Cytochrome P450 Induction: An Industry Perspective

Hariparsad N, et al. Clinical Pharmacology & Therapeutics.  December 2021,  Volume 112, Issue 4 p. 770-781. 

IF=7.051

PBPK的建模与模拟和治疗药物的监测：抗生素给药剂量调整的可能途径

PBPK Modeling and Simulation and Therapeutic Drug Monitoring: Possible Ways for Antibiotic Dose Adjustment

Ferreira A, Lapa R, Vale N. Processes. 2021, 9(11), 2087. IF=3.352

优化胃绕道手术后药物吸收的计算机建模：以二甲双胍为案例

Optimized In Silico Modeling of Drug Absorption after Gastric Bypass: The Case of Metformin

Dahan A, Porat D, Markovic M, Zur M, Kister O, Langguth P. Pharmaceutics. 2021, 13(11), 1873. IF=6.525

通过不同的应用策略评估不同超级崩解剂对FDM 3D 打印片剂药物释放的影响：体外试验-计算机预测评估

The evaluation of the effect of different superdisintegrants on the drug release from FDM 3D printed tablets through different applied strategies: In vitro-in silico assessment

Duranovic M, Madzarevic M, Ivkovic B, Ibric S, Cvijić S. International Journal of Pharmaceutics. Volume 610, 15 December 2021, 121194. 

IF=6.51

使用具有生物相关力的溶出介质进行BCS II 类药物依法韦仑片的虚拟生物利用度预测，从而开展IVIVR的研究和制剂处方变更的模拟

In silico bioavailability for BCS class II efavirenz tablets using biorelevant dissolution media for IVIVR and simulation of formulation changes

da Silva TM, da Silva Honorio T, da Cunha Chaves MH, Duque MD, Cabral LM, de Carvalho Patricio BF, Rocha HVA. Drug Development and Industrial Pharmacy. Volume 47, 2021 - Issue 8.  IF=3.727

抗生素阿米卡星、庆大霉素、妥布霉素和万古霉素的 PBPK 建模和模拟在临床实践中的应用

PBPK Modeling and Simulation of Antibiotics Amikacin, Gentamicin, Tobramycin, and Vancomycin Used in Hospital Practice

Ferreira A, Martins H, Oliveira JC, Lapa R, Vale N. Life. 2021, 11(11), 1130.  IF=3.253

开发PBPK模型，用于标准的结核病护理和新型抗结核药物

Development of physiologically-based pharmacokinetic models for standard of care and newer tuberculosis drugs

Humphries H, Almond L, Berg A, Gardner I, Hatley O, Small B, Zhang M, Jamei M, Romero K, Pan X. Pharmacometrics & Systems Pharmacology. Volume 10, Issue 11. IF=4.938

巴氯芬在子宫内暴露后，足月新生的PK：案例报告

Pharmacokinetics of Baclofen in a Full-Term Newborn after Intrauterine Exposure: A Case Report

Balakirouchenane D, Khoudour D, Chouchana D, Chevillard L, Declèves X. Neonatology. (2021) 118 (5): 624–627.  IF=5.106

使用基于生理学的生物药剂学(PBBM) 模型建立速释口服制剂的生物等效性安全空间：案例研究

Establishing the Bioequivalence Safe Space for Immediate-Release Oral Dosage Forms Using Physiologically Based Biopharmaceutics Modeling (PBBM): Case Studies

Heimbach T, Kesisoglou F, Novakovic J, Tistaert C, Mueller-Zsigmondy M, Kollipara S, Ahmed T, Mitra A, Suarez-Sharp S. Journal of Pharmaceutical Sciences. VOLUME 110, ISSUE 12, P3896-3906, December 2021.  IF=3.784

人体关节内注射给药的PBPK模型建立：甲氨蝶呤溶液与类风湿性关节炎的案例研究

Development of PBPK model for intra-articular injection in human: methotrexate solution and rheumatoid arthritis case study

Le Merdy M, Mullin JM, Lukacova V. Journal of Pharmacokinetics and Pharmacodynamics. (2021) 48:909–922.  IF=2.410

PBPK 模型作为预测和理解尿苷 5'-二磷酸-葡萄糖醛酸基转移酶底物在肠道代谢过程的工具

PBPK Modeling as a Tool for Predicting and Understanding Intestinal Metabolism of Uridine 5′-Diphospho-Glucuronosyltransferase Substrates

Reddy MB, Bolger MB, Fraczkiewicz G, Del Frari L, Luo L, Lukacova V, Mitra A, Macwan JS, Mullin JM, Parrott N, Heikkinen AT. Pharmaceutics. 2021, 13(9), 1325. IF=6.51

计算药剂学— 一种新的药物递送研究范式

Computational pharmaceutics – A new paradigm of drug delivery

Wang W, Ye Z, Gao H, Ouyang D. Journal of Controlled Release.  Volume 338, 10 October 2021, Pages 119-136.  IF=11.467

用体外试验-计算机预测工具简化 Acalabrutinib 无定形固体分散片的开发

In Vitro-In Silico Tools for Streamlined Development of Acalabrutinib Amorphous Solid Dispersion Tablets

Mudie DM, Stewart AM, Rosales JA, Adam MS, Morgen MM, Vodak DT. Pharmaceutics. 2021, 13(8), 1257. IF=6.51

开发利伐沙班的微乳水凝胶，用于透皮治疗和预防静脉血栓栓塞

Development of rivaroxaban microemulsion-based hydrogel for transdermal treatment and prevention of venous thromboembolism

Araújo CDCB, Simon A, Honório TDS, Da Silva SVC, Valle IMM, Da Silva LCRP, Rodrigues CR, de Sousa VP, Cabral LM, Sathler PC, do Carmo FA. Colloids and Surfaces B: Biointerfaces. Volume 206, October 2021, 111978. IF=5.999

结合BCS分类系统和PBPK模型, 预测黄芩素的体外和体内吸收特性

Combination of a biopharmaceutic classification system and physiologically based pharmacokinetic models to predict absorption properties of baicalein in vitro and in vivo

Liu Y, Sun J, Zhong L, Li Y, Er AN, Li T, Yang L, Dong L. Journal of Traditional Chinese Medical Sciences.Volume 8, Issue 3, July 2021, Pages 238-247.

CiteScore=1.5

用六种计算机预测模型评估欧洲化妆品的皮肤渗透性

Cosmetics Europe evaluation of 6 in silico skin penetration models

Grégoire S, Sorrell I, Lange D, Najjar A, Schepky A, Ellison C, Troutman J, Fabian E, Duplan H, Géniès C, Jacques-Jamin C, Klaric M, Hewitt NJ. Computational Toxicology. Volume 19, August 2021, 100177. 

CiteScore=5.6

使用人源化小鼠定量预测 P-gp介导的药物相互作用和在肠道的吸收

Predicting quantitatively P-glycoprotein mediated drug-drug interactions and intestinal absorption using humanized mice

Miyake T, Tsutsui H, Haraya K, Tachibana T, Morimoto K, Takehara S, Ayabe M, Kazuki Y. British Journal of Pharmacology. Volume 178, Issue 21 p. 4335-4351. IF=9.473

通过热力学和计算学的溶解度模型、GastroPlus软件预测、酮康唑皮下给药的细胞研究，来选择生物相容性溶剂

Biocompatible solvent selection based on thermodynamic and computational solubility models, in-silico GastroPlus prediction, and cellular studies of ketoconazole for subcutaneous delivery

Hussain A, Alshehri S, Ramzan M, Afzal O, Altamimi ASA, Alossaimi MA. Journal of Drug Delivery Science and Technology. Volume 65, October 2021, 102699. IF=5.062

通过计算机模拟和模拟指导口服药物在虚拟人群中的生物等效性试验

In Silico Modeling and Simulation to Guide Bioequivalence Testing for Oral Drugs in a Virtual Population

Zhang F, Gao H, Jia F, Wu X, Liu B, Wang H. Clinical Pharmacokinetics.  volume 60, pages1373–1385 (2021).  IF=5.577

通过实验获得的酮康唑溶解度，模型验证， 并用GastroPlus 预测该药物的体内情况

Experimental Solubility of Ketoconazole, Validation Models, and In vivo Prediction in Human Based on GastroPlus

Hussain A, Altamimi MA, Alshehri S, Imam SS, Haque MW. AAPS PharmSciTech. volume 22, Article number: 194 (2021).  IF=3.951

采用PBPK 建模方法预测药物在妊娠受试者和胎儿经肾脏的清除行为

PBPK Modeling Approach to Predict the Behavior of Drugs Cleared by Kidney in Pregnant Subjects and Fetus

Szeto KX, Le Merdy M, Dupont D, Bolger MB, Lukacova V. The AAPS Journal. (2021) 23: 8.  IF=3.603

应用双重机制方法支持比拉斯汀在老年患者的给药剂量选择

Application of a dual mechanistic approach to support bilastine dose selection for older adults

Kim CMJ, Lo Re V, Rodriguez M, Lukas JC, Leal N, Campo C, García-Bea A, Suarez E, Schmidt S, Vozmediano V. Pharmacometrics & Systems Pharmacology. Volume 10, Issue 9 p. 1006-1017.  IF=4.938

使用PBPK模型预测药物-食物相互作用：提高低置信度食物影响模型预测性能的建议

Use of Physiologically Based Pharmacokinetic Modeling for Predicting Drug–Food Interactions: Recommendations for Improving Predictive Performance of Low Confidence Food Effect Models

Wagner C, Kesisoglou F, Pepin XJ, Parrott N, Emami Riedmaier A. The AAPS Journal. volume 23, Article number: 85 (2021). IF=3.603

DRL ABC 缓释片的基于生理学的生物药剂学PBBM模型的开发、验证和应用，以证明其溶出度标准变更的合理性

Development, validation and application of physiologically based biopharmaceutics model to justify the change in dissolution specifications for DRL ABC extended release tablets

Jaiswal S, Ahmed T, Kollipara S, Bhargava M. Drug Development and Industrial Pharmacy. Volume 47, 2021 - Issue 5. IF=3.727

采用氨甲环酸在健康受试者的静脉内、肌内、皮下和口服给药数据开展基于生理的药代动力学建模

Physiologically based modelling of tranexamic acid pharmacokinetics following intravenous, intramuscular, sub-cutaneous and oral administration in healthy volunteers

Zoe Kane, Roberto Picetti, Alison Wilby, Joseph. Standing, Stanislas Grassin-Delyle, Ian Roberts, Haleema Shakur-Still. Eur J Pharm Sci. 2021 Sep 1; 164: 105893. IF=5.112

二甲双胍在9个不同物种体内的吸收和处置药代动力学的荟萃评估

Meta-Assessment of Metformin Absorption and Disposition Pharmacokinetics in Nine Species

Jeong YS, Jusko WJ. Pharmaceuticals. 2021, 14(6), 545. IF=5.215

模拟瑞德西韦的药代动力学及其药物相互作用

Simulation of Remdesivir Pharmacokinetics and Its Drug Interactions

Deb S, Reeves AA. Journal of Pharmacy & Pharmaceutical Sciences. VOL. 24 (2021): Pages 267 – 399. IF=3.337

应用基于生理学的生物药剂学PBBM模型了解溶出差异对速释药品体内性能的影响：以比索洛尔为例

Application of physiologically based biopharmaceutics modeling (PBBM) to understand the impact of dissolution differences on in vivo performance of immediate release products: The case of bisoprolol

Macwan J, Fraczkiewicz G, Bertolino M, Kruger M, Peters SA. Pharmacometrics & Systems Pharmacology. Volume 10, Issue 6 p. 622-632. IF=4.938

口服 APX3330 治疗可减少临床前小鼠模型中的 L-CNV 损伤，并使用 PBPK 模型确认 DR/DME 2 期临床试验的给药剂量在人的视网膜中有足够的分布

Oral APX3330 treatment reduces L-CNV lesions in preclinical mouse model and confirms Phase 2 DR/DME clinical dose with sufficient distribution to human retina using PBPK modeling

Silva LL, Lambert-Cheatham N, Stratford RE, Quinney SK, Corson TW, Kelley MR. Investigative Ophthalmology & Visual Science. June 2021, Vol.62, 1073.  IF=4.799

餐后状态下给药但控制其不在结肠释放，可增加 DF030263 的口服生物利用度，DF030263 是一种潜在的治疗慢性淋巴细胞白血病候选药物

Administration in fed state but not controlled release in the colon increases oral bioavailability of DF030263, a promising drug candidate for chronic lymphocytic leukemia

Lee JB, Zang X, Zgair A, Ooi TQ, Foley DW, Voronin G, Kagan L, Soukarieh F, Gao R, Shao H, Soh WT, Kim TH, Kim MG, Yun HY, Wilson AJ, Fischer PM, Gershkovich P. European Journal of Pharmaceutics and Biopharmaceutics. Volume 165, August 2021, Pages 106-112.  IF=5.589

通过骨架跃迁的策略产生系列蛋白酶抑制剂，获得用于治疗内脏利什曼病的临床前候选药物

Scaffold-Hopping Strategy on a Series of Proteasome Inhibitors Led to a Preclinical Candidate for the Treatment of Visceral Leishmaniasis

Thomas M, et al. J. Med. Chem. 2021, 64, 9, 5905–5930. IF=8.039

使用基于生理的生物药剂学PBBM模型和虚拟临床试验，评估胃肠道生理特性对药物的体内性能的影响

Evaluating the impact of physiological properties of the gastrointestinal tract on drug in vivo performance using Physiologically Based Biopharmaceutics Modeling and virtual clinical trials

Jereb R, Opara J, Bajc A, Petek B. Journal of Pharmaceutical Sciences. VOLUME 110, ISSUE 8, P3069-3081, August 2021.  IF=3.784

模拟拉替吡啶的舌下含服给药，考察其临床PK

Clinical pharmacokinetic study of latrepirdine via in silico sublingual administration

Santos J, Lobato L, Vale N. In Silico Pharmacology. volume 9, Article number: 29 (2021).  IF=4.3

利福平皮下给药的实验溶解度、热力学/计算验证和基于 GastroPlus 的计算机预测

Experimental Solubility, Thermodynamic/Computational Validations, and GastroPlus-Based In Silico Prediction for Subcutaneous Delivery of Rifampicin

Mahdi WA, Hussain A, Altamimi MA, Alshehri S, Bukhari SI, Ahsan MN. AAPS PharmSciTech.volume 22, Article number: 116 (2021).

IF=3.951

氨氯地平/缬沙坦临时配置的混悬液和对应的生理学建模

Extemporaneous Compounding and Physiological Modeling of Amlodipine/Valsartan Suspension

Radwan A, Naser Zaid A, Shraim N, Aabed WJ. International Journal of Hypertension. Mar 2021.  IF=2.434

使用新定义的参考化合物阈值开展新一代抗雄激素在人体内暴露的评估

Next generation risk assessment of human exposure to anti-androgens using newly defined comparator compound values

van Tongeren TCA, Moxon TE, Dent MP, Li H, Carmichael PL, Rietjens IMCM. Toxicology in Vitro. Volume 73, June 2021, 105132. IF=3.685

脂质制剂的体外和体内相关性：现状和未来前景

In vitro and in vivo correlation for lipid-based formulations: Current status and future perspectives

Huang Y, Yu Q, Chen Z, Wu W, Zhu Q, Lu Y. Acta Pharmaceutica Sinica B. Volume 11, Issue 8, August 2021, Pages 2469-2487. IF=14.907

药物在狗胃肠道区域和结肠中吸收的基于生理学的生物药剂学PBBM模型

Physiologically Based Biopharmaceutics Modeling of Regional and Colon Absorption in Dogs

Eckernäs E, Tannergren C. Mol. Pharmaceutics. 2021, 18, 4, 1699–1710.  IF=5.364

将口服药物开发提升到新水平：IMI 资助的 OrBiTo 项目对患者享有医疗的影响

Leveraging Oral Drug Development to a Next Level: Impact of the IMI-Funded OrBiTo Project on Patient Healthcare

Hens B, Augustijns P, Lennernäs H, McAllister M, Abrahamsson B. Front. Med., 05 March 2021. Volume 8. IF=5.058 

新型2-硫代-咪唑啶-4-One-伯氨喹的合成、生物活性及计算机预测药代动力学

Synthesis, Biological Activity and In Silico Pharmacokinetic Prediction of a New 2-Thioxo-Imidazoldidin-4-One of Primaquine

Pereira M, Caljon G, Gouveia MJ, Maes L, Vale N. Pharmaceuticals. 2021, 14(3), 196.  IF=5.215

开发长春瑞滨的透皮水凝胶制剂，评估其体外特性和抗黑色素瘤细胞的活性，并通过计算机模拟预测药物的吸收

Development of transdermal based hydrogel formulations of vinorelbine with an evaluation of their in vitro profiles and activity against melanoma cells and in silico prediction of drug absorption

Fonseca AM, Araújo CCB, Henriques da Silva J, Honorio TS, Nasciutti LE, Cabral LM, Almada do Carmo F, Pereira de Sousa V. Journal of Drug Delivery Science and Technology. Volume 63, June 2021, 102449. IF=6.062

了解低剂量干粉吸入制剂中的载药性能：体外试验-计算机预测方法

Understanding Carrier Performance in Low-Dose Dry Powder Inhalation: An In Vitro–In Silico Approach

Pinto JT, Cachola I, Pinto JF, Paudel A. Pharmaceutics. 2021, 13(3), 297. IF=6.51

PBPK吸收的建模与模拟在生物药剂学领域及在美国FDA新药申报中的应用

Biopharmaceutics Applications of Physiologically Based Pharmacokinetic Absorption Modeling and Simulation in Regulatory Submissions to the U.S. Food and Drug Administration for New Drugs

Wu F, Shah H, Li M, Duan P, Zhao P, Suarez S, Raines K, Zhao Y, Wang M, Lin HP, Duan J, Yu L, Seo P. The AAPS Journal. volume 23, Article number: 31 (2021). IF=3.603

药物的口服吸收研究的当前挑战和未来前景：UNGAP 络的观点

Current challenges and future perspectives in oral absorption research: An opinion of the UNGAP network

Vinarov Z, et al. Advanced Drug Delivery Reviews. Volume 171, April 2021, Pages 289-331.  IF=17.873

含有盐酸普萘洛尔的口腔粘膜明胶吸收膜：机理、口腔粘膜、生物药剂学性质的评估

Mucoadhesive Gelatin Buccal Films with Propranolol Hydrochloride: Evaluation of Mechanical, Mucoadhesive, and Biopharmaceutical Properties

Jovanović M, Tomić N, Cvijić S, Stojanović D, Ibric S, Uskoković P. Pharmaceutics. 2021, 13(2), 273. IF=6.51

酮康唑的热力学，在有机溶剂中计算的溶解度参数，和通过GastroPlus软件预测相关性质

Thermodynamic, Computational Solubility Parameters in Organic Solvents and In Silico GastroPlus Based Prediction of Ketoconazole

Alshehri S, Hussain A, Ahsan MN, Ali R, Siddique MUM. ACS Omega. 2021, 6, 7, 5033–5045.  IF=4.132

NITD-688，一种登革热病毒NS4B蛋白的泛血清型抑制剂，在临床前动物模型中显示出良好的药代动力学和药效

NITD-688, a pan-serotype inhibitor of the dengue virus NS4B protein, shows favorable pharmacokinetics and efficacy in preclinical animal models

Moquin SA, et al. Science Translational Medicine. 3 Feb 2021.  IF=19.319

使用先进的药物技术开发激酶抑制剂作为抗贾第鞭毛虫病治疗的一个奇案

A Curious Case for Development of Kinase Inhibitors as Antigiardiasis Treatments Using Advanced Drug Techniques

Michaels SA, Hennessey KM, Paragas N, Paredez AR, Ojo KK. ACS Infect. Dis. 2021, 7, 5, 943–947. IF=5.578

使用PBPK模型定量分析 P-pg对艾多沙班体内处置的影响

Quantitative analysis of an impact of P-glycoprotein on edoxaban’s disposition using a human physiologically based pharmacokinetic (PBPK) model

Kato T, Mikkaichi T, Yoshigae Y, Okudaira N, Shimizu T, Izumi T, Ando S, Matsumoto Y. International Journal of Pharmaceutics. Volume 597, 15 March 2021, 120349.  IF=6.51

盐酸乐卡地平多晶型的探索性研究：pH 依赖的溶解行为及模拟其对PK的影响

Exploratory Study on Lercanidipine Hydrochloride Polymorphism: pH-Dependent Solubility Behavior and Simulation of its Impact on Pharmacokinetics

Repin IA, Loebenberg R, DiBella J, Conceicao ACL, Minas da Piedade ME, Ferraz HG, Issa MG, Bou-Chacra NA, Ermida CFM, de Araujo GLB. AAPS PharmSciTech. volume 22, Article number: 54 (2021) Published: 21 January 2021. IF=3.951

体外试验-体内试验-计算机预测方法在吸入药品开发中的应用：以布地奈德纳米晶制剂作为模型药物

In vitro – in vivo – in silico approach in the development of inhaled drug products: nanocrystal-based formulations with budesonide as a model drug

Shi C, Ignjatovic J, Liu T, Han M, Cun D, Duriš J, Yang M, Cvijić S. Asian Journal of Pharmaceutical Sciences. Volume 16, Issue 3, May 2021, Pages 350-362.  IF=9.289

用Middle-out方法理解事物影响的机理，并开发可靠的PBPK 模型

Understanding Mechanisms of Food Effect and Developing Reliable PBPK Models Using a Middle-out Approach

Pepin XJ, Huckle JE, Alluri RV, Basu S, Dodd S, Parrott N, Emami Riedmaier A. The AAPS Journal. volume 23, January 2021. IF=3.603

使用 PBPK 模型和治疗药物监测进行万古霉素的药代动力学预测研究

In silico pharmacokinetic study of vancomycin using PBPK modeling and therapeutic drug monitoring

Ferreira A, Martins H, Oliveira JC, Lapa R, Vale N. Curr Drug Metab. 2021;22(2):150-162. IF=3.685

PDF 版文献汇总列表下载

https://www.jianguoyun.com/p/Dfeep1oQ_a64Bxiz9JIFIAA

(复制到浏览器）